Pediatric Hodgkin Lymphoma in Low- and Middle-Income Countries (LMICs). A Narrative Review.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
Pediatric Hodgkin lymphoma (HL) is a curable disease for more than 90% of children and adolescents in high-income countries. However, similar results cannot be achieved, particularly for advanced disease, in low- and middle-income countries (LMICs), where challenging socio-economic realities and the consequent scarcity of local resources heavily impact the treatment and patients' outcome. Information regarding the management and outcome of pediatric HL in LMICs is still limited. In this narrative review, we summarize the results reported in the literature so far and discuss the critical key points that have emerged from this overview.